middle.news
Immutep Secures FDA Nod on Efti Dose, Accelerates Lung Cancer Trial
8:37am on Monday 13th of October, 2025 AEDT
•
Biotechnology
Read Story
Immutep Secures FDA Nod on Efti Dose, Accelerates Lung Cancer Trial
8:37am on Monday 13th of October, 2025 AEDT
Key Points
FDA confirms 30 mg as optimal biological dose for efti
Successful completion of Project Optimus requirements
TACTI-004 (KEYNOTE-F91) Phase III trial sites opening in US
Efti combined with Merck’s KEYTRUDA for first-line NSCLC
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE